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ABSTRACT
Objectives: The aim of the study was to evaluate the levels of adipokines such as adiponectin, resistin, leptin as well as 
C-peptide in overweight and obese pregnant women.
Material and methods: The adipokines and C-peptide concentrations were measured in the group of 38 overweight/obese 
pregnant women (BMI > 25 kg/m2) and in 42 pregnant women of normal weight (BMI < 25 kg/m2) with ELISA tests between 
24th and 34th weeks of gestation. 
Results: The overweight/obese women compared to lean ones were characterized by significantly higher concentrations 
of leptin (43.44 ± 31.41 vs. 21.29 ± 12.67 ng/mL, p = 0.0001) and C-peptide (2.77 ± 1.88 vs. 2.25 ± 1.42 ng/mL, p = 0.034). 
There were no significant differences between groups in resistin (17.39 ± 7.59 vs. 15.76 ± 6.64 ng/mL, NS) and adiponectin 
(6.93 ± 3.52 vs. 8.07 ± 6.53 µg/mL, NS) levels. In the overweight/obese patients, no relationships between the adipokines, 
C-peptide and CRP concentrations were found. BMI was negatively correlated with the resistin levels (R = –0.406, p = 0.011). 
The significant correlation between leptin and C-peptide concentrations was observed in the study group (R = 0.517, 
p = 0.012). In the control group, the negative correlation between adiponectin concentrations and BMI was shown 
(R = –0.446, p = 0.003). 
Conclusions: The higher levels of leptin in the overweight and obese pregnant women seem to reflect the leptin resistance 
condition and the higher levels of C-peptide in this group is suggestive for hyperinsulinemia. The positive correlation between 
C-peptide and leptin levels but not with resistin and adiponectin might confirm the role of leptin in the hyperinsulinemia 
development in overweight and obesity during pregnancy. 
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INTRODUCTION
In the past few decades, a dramatic increase in the inci-
dence of overweight and obesity in women of child-bearing 
age has been observed. According to the Australian data, it 
has been estimated that about 15% of women aged 25 to 
34 years (the highest fertility age) were obese [1]. 
The overweight and obesity usually are defined in terms 
of the body mass index (BMI): BMI ≥ 25 kg/m2 indicates 
overweight and ≥ 30 kg/m2 — obesity. Overweight and 
obesity in pregnancy, even without chronic diseases before 
conception, are the risk factors of adverse obstetric and neo-
natal outcomes: the prevalence of gestational hypertension 
and preeclampsia, gestational diabetes mellitus (GDM), ce-
sarean delivery, and labour induction increases. Similarly, 
neonatal risks rise up with the maternal BMI augmenta-
tion including preterm birth below 32nd week of gestation, 
macrosomia, transient tachypnea, sepsis, and an intensive 
care unit admission [2]. 
Children of obese mothers are exposed to the develop-
ment of the childhood obesity and metabolic syndrome in 
the adult life. A phenomenon described as “fetal program-
ming” or “developmental origin of adult disease” refers to 
the abnormal intrauterine fetal development [3, 4]. The 
data indicate that adipocytokines may play a critical role 
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in this process. The name of adipocytokine (adipokine) is 
given to any protein that can be synthesized and secreted 
by adipocytes. These molecules are involved in controlling 
and the regulation of the appetite and energy balance, the 
angiogenesis, inflammation, immunity, blood pressure, insu-
lin sensitivity, glucose homeostasis, nutrient transport, and 
lipid metabolism. Their synthesis is altered in obesity, type 
2 diabetes and metabolic syndrome [5]. Leptin, resistin and 
adiponectin representing adipokines family, all are known 
to be produced not only by adipose tissue but also within 
the intrauterine environment [6].
Leptin, the product of the ob gene, is involved in the 
regulation of energy homeostasis and is almost exclusively 
expressed and produced by the white adipose tissue [6]. 
The concentrations and adipose tissue mRNA expression of 
leptin are strongly associated with BMI and fat mass [7, 8]. 
The functions attributed to leptin are extensive, including the 
regulation of food intake and energy balance: it influences 
the inhibition of the insulin secretion, stimulates the glucose 
transport and acts as a signal to the reproductive system [7]. 
During pregnancy, the leptin levels are two- to three-fold 
higher than in non-pregnancy conditions with the maximum 
concentrations at 28th week and the decrease to the pregravid 
values after delivery. The placenta is a significant source of 
the maternal circulating leptin, which is positively correlated 
with the fat mass during pregnancy [9]. Although the leptin 
levels typically correlate with adipose tissue mass, it has been 
shown that obese individuals had the elevated leptin levels 
without the expected anorexic responses. This observation 
could suggest the leptin resistance in obesity [10]. Pregnancy 
is considered a leptin-resistant state as well [11]. 
Resistin is believed to promote the insulin resistance 
by increasing the storage of triglycerides in muscles and 
the liver, instead of the adipose tissue [12]. It is also highly 
expressed in macrophages and monocytes suggesting that 
it may influence the insulin resistance via the inflamma-
tory pathways [13]. The resistin levels have been shown to 
be negatively correlated to waist-hip ratio and positively 
correlated with body fat mass which would be consistent 
with a role of resistin in the insulin resistance development 
[14]. Opposite to this opinion, some studies do not con-
firm the correlation between the resistin plasma levels, BMI 
and the insulin resistance [15]. The resistin concentrations 
in pregnant women are significantly higher as compared 
to non-pregnant controls and increase as pregnancy pro-
gresses. It has been postulated that these levels correlate 
with the insulin resistance in the late gestation [16]. 
Adiponectin is considered as an insulin-sensitizing, 
anti-inflammatory and anti-atherogenic adipokine. It stimu-
lates the glucose uptake in skeletal muscles and reduces the 
hepatic glucose synthesis [17]. The adiponectin concentra-
tions are lower in obese and/or type 2 diabetic patients. The 
inverse correlation between the adiponectinemia and 
obesity, particularly the abdominal obesity, and the strong 
positive correlation between the adiponectin levels and the 
insulin sensitivity were observed. The results of experimental 
studies indicate the protective role of adiponectin against 
obesity-related metabolic diseases [18]. The adiponectin 
expression is inhibited by pro-inflammatory cytokines, hy-
poxia, and oxidative stress which all are conditions typically 
associated with obesity [19]. It has been observed that in 
pregnancy the maternal adiponectin secretion progressively 
declines [20]. It has been found that the plasma adiponectin 
levels and mRNA expression were negatively correlated with 
the fat mass. This observation may imply the association 
between the adipose tissue accretion and signals for lower-
ing adiponectin production even in the absence of obesity. 
C-peptide, the 31 amino-acid residues formed during 
cleavage of insulin from proinsulin, is released by the pan-
creatic β cell in equimolar amounts with insulin. It is an in-
dependent marker of insulin biosynthesis and secretion [21]. 
The data analyzing the levels of adipocytokines in nor-
mal and complicated pregnancies are ambiguous. Recogniz-
ing the significance of adipose tissue and its hormones in 
terms of the appropriate metabolic control in pregnancy, 
we decided to evaluate the concentrations of adipokines 
such as leptin, resistin, adiponectin, as well as, C-peptide in 
overweight and obese pregnant women. 
MATERIAL AND METHODS
Thirty-eight overweight and obese women (BMI > 
> 25.0 kg/m2) and forty-two healthy pregnant women 
(BMI < 25.0 kg/m2) were included to the study which was 
performed in Department of Obstetrics and Perinatology, 
Medical University in Lublin. All of them gave informed 
consent to participate in the study, which had been pre-
viously approved by the Bioethical Review Board of the 
Medical University in Lublin. The body mass index (BMI) 
was assessed based on weight measurement at the first 
prenatal visit before the 8th week of gestation. The inclu-
sion criteria for the study were as follows: gestational age 
between 24th and 34th week as determined on ultrasound 
before the 20th week, first prenatal visit before 8th week, 
singleton pregnancy. The exclusion criteria for the study 
were as follows: pre-pregnancy diabetes mellitus, chronic 
and gestational hypertension, preeclampsia, chronic renal 
disease, intrauterine growth retardation, liver diseases, in-
flammation and infectious diseases — the patients with 
a positive urine or vaginal culture were excluded from the 
study as well as cigarette smokers. 
The oral glucose tolerance test (OGTT) with 75 g of 
glucose in compliance with WHO standards was performed 
in all women in the study and in the control group between 
24th and 28th week of gestation. In the test day, glucose 
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performed. The Spearman rank test was employed for 
searching correlations between variables. The statistical 
significance was defined as p < 0.05.
RESULTS
The studied groups did not differ with regard 
to the baseline descriptors: age (30.42 ± 5.31 vs. 29.24 ± 
± 5.92 years, NS), gestational age (29.13 ± 3.16 vs. 29.40 ± 
± 2.89 hbd, NS). The BMI value was significantly high-
er in overweight/obese patients than in lean ones 
(32.68 ± 5.12 vs. 21.07 ± 2.13 kg/m2, p < 0.000001) as well as CRP 
concentrations (12.69 ± 27.15 vs. 6.62 ± 13.54 mg/L, p = 0.014). 
The glucose levels in OGTT at 1st and 2nd hour were compara-
ble between groups (1st hour: 162.00 ± 37.10 vs. 148.26 ± 42.20, 
NS; 2nd hour: 146.91 ± 42.65 vs. 129.07 ± 45.80, NS); fasting 
glucose levels were higher in overweight/obese women 
(91.44 ± 18.14 vs. 84.38 ± 12.00, p = 0.05), but the difference 
was not statistically significant (Tab. 1). 
The patients in the study group compared to control one 
were characterized by significant higher concentrations of 
leptin (43.44 ± 31.41 vs. 21.29 ± 12.67 ng/mL, p = 0.0001) 
and C-peptide (2.77 ± 1.88 vs. 2.25 ± 1.42 ng/mL, p = 0.034). 
There were no significant differences between groups in the 
levels of resistin (17.39 ± 7.59 vs. 15.76 ± 6.64 ng/mL, NS) and 
adiponectin (6.93 ± 3.52 vs. 8.07 ± 6.53 µg/mL, NS) (Tab. 2). 
In the study group, no relationships between the adi-
pokines, C-peptide and CRP concentrations were found. 
The BMI was negatively correlated with the resistin levels 
(R = –0.406, p = 0.011) and the positive correlation, not statisti-
cally significant, was marked with the leptin levels (R = 0.319, 
p = 0.05). The significant correlation between the leptin and 
C-peptide concentrations was found in overweight/obese 
patients (R = 0.517, p = 0.012) (Tab. 3). In the control group, 
only the negative correlation between the adiponectin con-
centrations and BMI was shown (R = –0.446, p = 0.003) (Tab. 4). 
levels were measured fasting and at 1st and at 2nd hour after 
glucose loading. The glucose levels were measured in ve-
nous blood plasma with the use of glucose oxidase method 
(Cormay, Poland). The serum leptin, adiponectin, resistin, 
C-peptide and C-reactive protein (CRP) levels were assessed 
in all patients between 24th and 34th week of gestation. The 
blood samples were taken fasting together with samples 
for routinely performed laboratory tests. The samples were 
allowed to clot for at least 30 minutes before centrifugation 
at 1000 G, which was continued for 30 minutes. Serum has 
been removed and then frozen at –70° C. The leptin concen-
trations were measured by means of the sandwich enzyme 
immunoassay technique (Human Leptin Quantikine, R&D 
Systems Inc. Minneapolis, USA) as well as adiponectin (Hu-
man Adiponectin Quantikine, R&D Systems Inc. Minneapolis, 
USA), resistin (Human Resistin Quantikine, R&D Systems Inc. 
Minneapolis, USA) and C-peptide (C-peptide, DakoCytoma-
tion Ltd Ely, United Kingdom). CRP levels were measured 
with ELISA method (CRP Elisa Kit Immunodiagnostik AG, 
Bensheim, Germany). 
The study group was compared to the control one with 
respect of maternal and gestational age at the entry to the 
study, parity, BMI, CRP levels and glucose levels at each 
hour of OGTT as well as the leptin, adiponectin, resistin 
and C-peptide concentrations. The correlations between 
the leptin, adiponectin, resistin, C-peptide levels and BMI, 
and CRP concentrations were analyzed in the study and in 
the control group.
The Statistica 12.5 for Windows (StatSoft, Poland) was 
used for data analysis. The elements of descriptive statsistics 
were used. The data was presented as mean ± standard 
deviation. The Shapiro-Wilk test for normal distribution of 
the data and one-tailed Student’s t-test, or (in unequal vari-
ance) The Cochran-Cox test (absence of normal distribution 
and nonparametric data), and the Mann-Whitney U were 
Table 1. The characteristics of overweight/obese and lean pregnant women
BMI > 25 kg/m2
N = 38
BMI < 25 kg/m2
N = 42 p
Age 30.42 ± 5.31 29.24 ± 5.92 NS
Gestational age (hbd) 29.13 ± 3.16 29.40 ± 2.89 NS
Parity 1.82 ± 1.08 2.00 ± 1.15 NS
BMI [kg/m2] 32.68 ± 5.12 21.07 ± 2.13 P < 0.000001
CRP [mg/L] 12.69 ± 27.15 6.62 ± 13.54 p = 0.014
Glucose [mg/dL] 0’ 91.44 ± 18.14 84.38 ± 12.00 p = 0.05
1’ 162.00 ± 37.10 148.26 ± 42.20 NS
2’ 146.91 ± 42.65 129.07 ± 45.80 NS
BMI — body mass index; CRP — C-reactive protein; p — statistical significance; NS — statistically not significant
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DISCUSSION
The overweight and obesity are associated with adverse 
reproductive health outcomes although the exact mecha-
nisms have not been identified yet. The human pregnancy 
is characterized by metabolic changes that promote the 
adipose tissue accretion in early gestation, followed by in-
sulin resistance in late pregnancy. The maternal obesity 
and placental-derived hormones are believed to play the 
significant role in insulin resistance development as well 
as other pregnancy-related conditions [2]. 
In this study, the overweight/obese pregnant women 
and the normal weight women were compared in respect 
of the adipokines levels such as adiponectin, leptin and 
resistin. It has been found that the adiponectin levels were 
comparable in both groups. The same result has been 
achieved by Ozias et al. who shown no difference in the 
concentrations of adiponectin between the normal and 
overweight/obese women in the third trimester of gestation 
[22]. Other authors have reported that the overweight and 
obese pregnant women had decreased adiponectin levels 
compared to the patients of normal weight [23]. The pos-
sible discrepancy between the results of this and previous 
research might be explained by the different criteria of the 
study protocol. In this study, the BMI value was assessed 
based on the patient’s weight before the 8th week of gesta-
tion whereas other authors took into consideration the BMI 
value in different stages of pregnancy what included also 
the gestational weight gain. 
In our study, the negative correlation between adiponec-
tin and BMI was observed only in the lean pregnant women. 
These results are intriguing since the lower adiponectin levels 
are thought to be characteristic of obesity apart from preg-
nancy [24]. Our observations partially confirm the results of 
the study presented by Ritterath C. et al. who have found no 
correlation between the adiponectin concentrations and BMI 
in pregnant women. They have shown that adiponectin levels 
were negatively correlated with triglyceride levels. Thus they 
are of opinion that the decrease in the adiponectin concen-
trations in pregnancy might be more closely connected with 
the changes in fat metabolism than with an increase in the 
Table 2. The adipokines and C-peptide concentrations in overweight/obese and lean pregnant women
BMI > 25 kg/m2
N = 38
BMI < 25 kg/m2
N = 42 P
Leptin [ng/mL] 43.44 ± 31.41 21.29 ± 12.67 p = 0.0001
Adiponectin [µg/mL] 6.93 ± 3.52 8.07 ± 6.53 NS
Resistin [ng/mL] 17.39 ± 7.59 15.76 ± 6.64 NS
C-peptide [ng/mL] 2.77 ± 1.88 2.25 ± 1.42 p = 0.034
BMI — body mass index; p — statistical significance; NS — statistically not significant
Table 3. The correlations between adipokines and C-peptide and BMI and CRP in overweight/obese pregnant women
BMI CRP C-peptide
p
R p R p R
Leptin 0.319 0.05 0.173 NS 0.517 0.012
Adiponectin –0.013 NS –0.017 NS –0.929 NS
Resistin –0.406 0.011 0.226 NS –0.125 NS
C-peptide 0.158 NS 0.087 NS — —
BMI — body mass index; CRP — C-reactive protein; R — Spearman correlation’s coefficient; p — statistical significance; NS — statistically not significant
Table 4. The correlations between adipokines and C-peptide and BMI and CRP in normal weight pregnant women
BMI CRP C-peptide
P
R p R p R
Leptin 0.033 NS 0.143 NS 0.193 NS
Adiponectin –0.446 0.003 –0.126 NS 0.043 NS
Resistin 0.071 NS 0.118 NS 0.038 NS
C-peptide 0.048 NS 0.040 NS — —
BMI — body mass index; CRP — C-reactive protein; R — Spearman correlation’s coefficient; p — statistical significance; NS — statistically not significant
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insulin resistance or the weight gain during pregnancy [25]. 
Another report has revealed that the adiponectin levels are 
strongly related to BMI in pregnant women at 24th–29th weeks 
of gestation but not to the glucose loading response [26]. In 
our study, no correlations between the adiponectin and glu-
cose levels in OGTT in both groups have been found. Hence, 
a mechanism or factors maintaining the adiponectin levels in 
overweight and obese pregnant women could be postulated. 
This hypothesis might be confirmed by the observation that 
not all overweight and obese women develop GDM during 
pregnancy which is thought to be associated with signifi-
cantly lower concentrations of this adipokine [27]. Cortelazzi 
et al. have found that the concentrations of circulating adi-
ponectin were lower in patients with GDM as compared to 
healthy pregnant women regardless of pre-pregnancy BMI 
and the insulin sensitivity [28].
The study of Mazaki-Tovi et al. has revealed that the 
adiponectin levels during the 1st, 2nd and 3rd trimester were 
comparable and were significantly higher than postpartum 
levels. The authors concluded that despite the increased 
insulin resistance as pregnancy progresses, there were no 
significant alterations in the adiponectin levels [29]. This may 
imply that the regulation of the adiponectin release during 
gestation is altered. The elevated gestational adiponectin 
levels could be consistent with the postulated increased 
“adiponectin resistance” during pregnancy. 
In the presented study, it has been found that the over-
weight/obese patients were characterized by the significantly 
higher concentrations of leptin compared to the lean ones 
what has been also observed by other researchers. The 
marked but not statistically significant positive correlation be-
tween BMI and the leptin levels in overweight/obese patients 
has been reported as well. Verhaeghe et al. have shown that 
the plasma levels of leptin, as well as the CRP concentrations, 
were strongly related to BMI in pregnant women at 24th–29th 
weeks of gestation [30]. Similarly, Qiu et al. have revealed that 
the elevated leptin concentrations were positively correlated 
with BMI and the insulin levels. After adjusting for age and 
BMI before pregnancy, GDM had an independent direct cor-
relation with leptin concentrations. Thus they have proposed 
that the leptin levels equal to or more than 20 ng/mL could 
be a useful marker in predicting the GDM development. 
Moreover, it appears that in early pregnancy hyperleptinemia, 
regardless of maternal adiposity, could be associated with 
an increased risk of GDM [31]. 
The results of the study published by Misra VK. and 
Trudeau S. have indicated that although overweight 
and obese women had significantly higher serum leptin 
concentrations than their non-overweight counterparts 
throughout pregnancy and these concentrations increased 
significantly across gestation for both groups, the rate of 
this increase was significantly smaller for overweight/obese 
women. The authors believed that factors others than the 
fat mass alone can influence the leptin concentrations in 
this group of patients [32]. This observation could explain 
the lack of significant correlation between the leptin levels 
in the overweight/obese as well as in the normal weight 
pregnant women and BMI in our study. 
There are conflicting data about the resistin levels during 
pregnancy. In this study, there were no significant differ-
ences between the overweight and obese and the lean preg-
nant women in the term of the resistin levels although the 
significant negative correlation between resistin levels and 
BMI in the study group has been reported. The opposite 
results have been presented by Hendler I. et al. who have 
found no correlations between the resistin levels and ma-
ternal BMI in the third trimester of pregnancy [27]. Thus the 
discrepancy between the results could be explained by the 
different study protocols. 
Megia A et al. have observed that patients with GDM had 
lower resistin levels than women with normal glucose toler-
ance. The association between low serum resistin levels and 
the diagnosis of GDM was independent of the degree of insulin 
sensitivity [33]. Some reports have revealed the higher serum 
resistin levels in the 1st, 2nd and 3rd trimesters of pregnancy and 
in GDM compared to non-pregnant control group [28]. These 
findings suggest that higher resistin levels could be associated 
with the decreased insulin sensitivity or could mediate the 
state of insulin resistance present during pregnancy. 
In the presented report, the study group was character-
ized by significantly higher CRP levels than in the control one 
but no correlations were found between CRP concentrations 
and BMI in both groups. There is an observation suggesting 
the presence of a chronic low-grade inflammation in obe-
sity with increased levels of several circulating markers of 
inflammation like C-reactive protein (CRP), tumor necrosis 
factor-alpha (TNF-α), interleukin-6 (IL-6), and others [34]. 
The results of our study might imply that in pregnancy the 
degree of inflammation, although significantly marked in 
the overweight /obese women, is not influenced by BMI 
itself in a direct way. Neither in the obese/overweight preg-
nant women nor in lean ones, relationships between the 
adipokines and CRP were found, which might postulate 
that their release during pregnancy is not affected by low, 
chronic inflammation condition associated with obesity. 
C-peptide, an independent marker of the insulin bio-
synthesis and secretion, seems to be a useful diagnostic 
tool in diabetology and related fields [35]. In this research, 
it has been observed that the C-peptide levels were sig-
nificantly higher in the overweight/obese pregnant women 
than in pregnant women of normal weight what is sug-
gestive for hyperinsulinemia in this group although there 
were no differences in glucose concentrations in OGTT test 
between groups. We could find no correlations between 
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the C-peptide levels and BMI both in the study and the 
control group what might suggest that C-peptide release 
during pregnancy are influenced not only by overweight 
and obesity. The positive correlation between the C-peptide 
and leptin concentrations in overweight/obese pregnant 
women could confirm the results of previous studies that 
have postulated the hyperleptinemia as one of the reasons 
for hyperinsulinemia [9, 12, 35].
CONCLUSIONS
The obesity in pregnant women is characterized by 
a higher concentration of leptin but not adiponectin and 
resistin. Thus it could be postulated that pregnancy has 
a similar influence on the synthesis and release of adi-
ponectin and resistin in the overweight and obese as well 
as in lean pregnant women. Some mechanisms and factors 
preventing the changes in these adipokines levels might 
be considered. It may be presumed that adiponectin and 
resistin might not be considered as the only factors related 
to the development of pregnancy complications connected 
with overweight and obesity. The higher levels of leptin 
in the overweight and obese pregnant women seem to 
reflect the leptin resistance condition and the higher levels 
of C-peptide in this group is suggestive for hyperinsuline-
mia. The positive correlation between C-peptide and leptin 
levels but not with resistin and adiponectin might confirm 
the role of leptin in the hyperinsulinemia development in 
overweight and obesity during pregnancy. 
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